Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries
Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme an...
Gespeichert in:
Veröffentlicht in: | The Journal of biological chemistry 1999-12, Vol.274 (50), p.35927-35932 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 35932 |
---|---|
container_issue | 50 |
container_start_page | 35927 |
container_title | The Journal of biological chemistry |
container_volume | 274 |
creator | Anderson, V E Zaniewski, R P Kaczmarek, F S Gootz, T D Osheroff, N |
description | Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding. |
doi_str_mv | 10.1074/jbc.274.50.35927 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_17455773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17455773</sourcerecordid><originalsourceid>FETCH-LOGICAL-p238t-46031f004d5d72b486f4551a330933676b1b71437009fa9534a50391d1290b2e3</originalsourceid><addsrcrecordid>eNo1kMtOwzAURL0A0VLYs0JesWvwM46XVXlVqkCIxzayE6d1lcTBjpH6E3wzBspsRhqNju4dAC4wyjAS7Hqnq4wIlnGUUS6JOAJThAieS8KLCTgNYYeSmMQnYIIRLzgTcgq-nqPtXet6E6Dtt1bbEd48LqA3rd2o0boedqa2ajQ11Hv4Mqphu29d5aoqBqiiN8lGNzgbXGe8Cgau3jO43Kp-84uEtY-bxKhSYkMHVeVdCNB8ujb-4JXfQ-1iXytvTTgDx41qgzk_-Ay83d2-Lh_m66f71XKxng-EFuOc5YjiJn1T81oQzYq8YZxjRSmSlOYi11gLzKhASDZKcsoUR1TiGhOJNDF0Bq7-uIN3H9GEsexsqEzbqt64GEosEk8ImoqXh2LUaYhy8LZLJ5f_C9Jvfo1zCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17455773</pqid></control><display><type>article</type><title>Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Anderson, V E ; Zaniewski, R P ; Kaczmarek, F S ; Gootz, T D ; Osheroff, N</creator><creatorcontrib>Anderson, V E ; Zaniewski, R P ; Kaczmarek, F S ; Gootz, T D ; Osheroff, N</creatorcontrib><description>Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.</description><identifier>ISSN: 0021-9258</identifier><identifier>DOI: 10.1074/jbc.274.50.35927</identifier><identifier>PMID: 10585479</identifier><language>eng</language><publisher>United States</publisher><subject>Anti-Infective Agents - pharmacology ; Biological Evolution ; Ciprofloxacin - pharmacology ; DNA Damage ; DNA religation ; DNA Repair - drug effects ; DNA Topoisomerase IV ; DNA Topoisomerases, Type II - drug effects ; DNA Topoisomerases, Type II - genetics ; DNA Topoisomerases, Type II - metabolism ; Escherichia coli - enzymology ; Etoposide - pharmacology ; Fluoroquinolones ; Gram-Positive Bacteria - drug effects ; Kinetics ; Quinolones - pharmacology ; Staphylococcus aureus ; Staphylococcus aureus - enzymology ; Staphylococcus aureus - genetics</subject><ispartof>The Journal of biological chemistry, 1999-12, Vol.274 (50), p.35927-35932</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10585479$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anderson, V E</creatorcontrib><creatorcontrib>Zaniewski, R P</creatorcontrib><creatorcontrib>Kaczmarek, F S</creatorcontrib><creatorcontrib>Gootz, T D</creatorcontrib><creatorcontrib>Osheroff, N</creatorcontrib><title>Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.</description><subject>Anti-Infective Agents - pharmacology</subject><subject>Biological Evolution</subject><subject>Ciprofloxacin - pharmacology</subject><subject>DNA Damage</subject><subject>DNA religation</subject><subject>DNA Repair - drug effects</subject><subject>DNA Topoisomerase IV</subject><subject>DNA Topoisomerases, Type II - drug effects</subject><subject>DNA Topoisomerases, Type II - genetics</subject><subject>DNA Topoisomerases, Type II - metabolism</subject><subject>Escherichia coli - enzymology</subject><subject>Etoposide - pharmacology</subject><subject>Fluoroquinolones</subject><subject>Gram-Positive Bacteria - drug effects</subject><subject>Kinetics</subject><subject>Quinolones - pharmacology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - enzymology</subject><subject>Staphylococcus aureus - genetics</subject><issn>0021-9258</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAURL0A0VLYs0JesWvwM46XVXlVqkCIxzayE6d1lcTBjpH6E3wzBspsRhqNju4dAC4wyjAS7Hqnq4wIlnGUUS6JOAJThAieS8KLCTgNYYeSmMQnYIIRLzgTcgq-nqPtXet6E6Dtt1bbEd48LqA3rd2o0boedqa2ajQ11Hv4Mqphu29d5aoqBqiiN8lGNzgbXGe8Cgau3jO43Kp-84uEtY-bxKhSYkMHVeVdCNB8ujb-4JXfQ-1iXytvTTgDx41qgzk_-Ay83d2-Lh_m66f71XKxng-EFuOc5YjiJn1T81oQzYq8YZxjRSmSlOYi11gLzKhASDZKcsoUR1TiGhOJNDF0Bq7-uIN3H9GEsexsqEzbqt64GEosEk8ImoqXh2LUaYhy8LZLJ5f_C9Jvfo1zCw</recordid><startdate>19991210</startdate><enddate>19991210</enddate><creator>Anderson, V E</creator><creator>Zaniewski, R P</creator><creator>Kaczmarek, F S</creator><creator>Gootz, T D</creator><creator>Osheroff, N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7TM</scope><scope>C1K</scope></search><sort><creationdate>19991210</creationdate><title>Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries</title><author>Anderson, V E ; Zaniewski, R P ; Kaczmarek, F S ; Gootz, T D ; Osheroff, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p238t-46031f004d5d72b486f4551a330933676b1b71437009fa9534a50391d1290b2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anti-Infective Agents - pharmacology</topic><topic>Biological Evolution</topic><topic>Ciprofloxacin - pharmacology</topic><topic>DNA Damage</topic><topic>DNA religation</topic><topic>DNA Repair - drug effects</topic><topic>DNA Topoisomerase IV</topic><topic>DNA Topoisomerases, Type II - drug effects</topic><topic>DNA Topoisomerases, Type II - genetics</topic><topic>DNA Topoisomerases, Type II - metabolism</topic><topic>Escherichia coli - enzymology</topic><topic>Etoposide - pharmacology</topic><topic>Fluoroquinolones</topic><topic>Gram-Positive Bacteria - drug effects</topic><topic>Kinetics</topic><topic>Quinolones - pharmacology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - enzymology</topic><topic>Staphylococcus aureus - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anderson, V E</creatorcontrib><creatorcontrib>Zaniewski, R P</creatorcontrib><creatorcontrib>Kaczmarek, F S</creatorcontrib><creatorcontrib>Gootz, T D</creatorcontrib><creatorcontrib>Osheroff, N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nucleic Acids Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anderson, V E</au><au>Zaniewski, R P</au><au>Kaczmarek, F S</au><au>Gootz, T D</au><au>Osheroff, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>1999-12-10</date><risdate>1999</risdate><volume>274</volume><issue>50</issue><spage>35927</spage><epage>35932</epage><pages>35927-35932</pages><issn>0021-9258</issn><abstract>Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.</abstract><cop>United States</cop><pmid>10585479</pmid><doi>10.1074/jbc.274.50.35927</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9258 |
ispartof | The Journal of biological chemistry, 1999-12, Vol.274 (50), p.35927-35932 |
issn | 0021-9258 |
language | eng |
recordid | cdi_proquest_miscellaneous_17455773 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Anti-Infective Agents - pharmacology Biological Evolution Ciprofloxacin - pharmacology DNA Damage DNA religation DNA Repair - drug effects DNA Topoisomerase IV DNA Topoisomerases, Type II - drug effects DNA Topoisomerases, Type II - genetics DNA Topoisomerases, Type II - metabolism Escherichia coli - enzymology Etoposide - pharmacology Fluoroquinolones Gram-Positive Bacteria - drug effects Kinetics Quinolones - pharmacology Staphylococcus aureus Staphylococcus aureus - enzymology Staphylococcus aureus - genetics |
title | Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A41%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quinolones%20inhibit%20DNA%20religation%20mediated%20by%20Staphylococcus%20aureus%20topoisomerase%20IV.%20Changes%20in%20drug%20mechanism%20across%20evolutionary%20boundaries&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Anderson,%20V%20E&rft.date=1999-12-10&rft.volume=274&rft.issue=50&rft.spage=35927&rft.epage=35932&rft.pages=35927-35932&rft.issn=0021-9258&rft_id=info:doi/10.1074/jbc.274.50.35927&rft_dat=%3Cproquest_pubme%3E17455773%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17455773&rft_id=info:pmid/10585479&rfr_iscdi=true |